Cytokine interest shows no sign of waning
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
The big approvals still on the cards for 2021
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Mapping the transatlantic divide for biotech flotations
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
The window of opportunity opens wider for Ascendis
With the previous incumbent withdrawn from the market Ascendis hails a new hormone replacement for hypoparathyroidism.
